These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 534675)

  • 1. Action of middle molecules from chronic renal insufficiency treated by hemodialysis on mitochondrial respiration.
    Rinaudo JB; Gallice P; Crevat A; Saingra S; Murisasco A
    Biomedicine; 1979 Oct; 30(4):215-8. PubMed ID: 534675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The evaluation of the efficacy of efferent therapy in patients with acute and chronic kidney failure by the spectrum of blood middle-molecule fractions].
    Kon'kova TA; Chudnovskaia MV; Golovanov SA
    Urol Nefrol (Mosk); 1994; (4):35-7. PubMed ID: 7985299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Middle molecules and the problem of endogenous intoxication in critical states of various etiologies].
    Vladyka AS; Levitskiĭ ER; Poddubnaia LP; Gabriélian NI
    Anesteziol Reanimatol; 1987; (2):37-42. PubMed ID: 3300433
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of haemodialysate and its peptide fractions on acetylcholinesterase activity in erythrocytes from healthy subjects and patients with terminal renal failure.
    Smoleński O; Tabarowski Z; Miszta H; Dabrowski Z
    Int Urol Nephrol; 1993; 25(5):503-8. PubMed ID: 8270380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "In vitro" inhibition of platelet aggregation by uremic middle molecules.
    Gallice P; Fournier N; Crevat A; Saingra S; Frayssinet R; Murisasco A; Sicardi F
    Biomedicine; 1980; 33(6):185-8. PubMed ID: 7213919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Action of medium-size molecules at the cell respiration level in hemodialysis patients].
    Murisasco A; Saingra S; Crevat A; Rinaudo JB; Gallice P
    J Urol Nephrol (Paris); 1979 Sep; 85(9):586-9. PubMed ID: 522203
    [No Abstract]   [Full Text] [Related]  

  • 7. Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment.
    Válek A; Dzúrik R; Spustová V; Válková D
    Artif Organs; 1981; 4 Suppl():173-6. PubMed ID: 7295088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Examination of lymphokines in patients with hemodialysis (author's transl)].
    Löcsey L; Kálmán K; Hauck M; Kakuk G
    Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythrocyte transport of middle molecular substances.
    Gajdos M; Spustová V; Geryková M; Dzúrik R
    Proc Eur Dial Transplant Assoc; 1981; 18():183-7. PubMed ID: 7329966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K; Kidawa Z; Walasek L; Lutz W
    Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
    [No Abstract]   [Full Text] [Related]  

  • 12. [Changes in the picture of chronic diseases on long-term hemodialysis treatment].
    von Appen K; Ivanovich P; Klinkmann H; Stetsiuk E
    Urol Nefrol (Mosk); 1995; (5):25-7. PubMed ID: 8571479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

  • 14. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
    Maduell F
    Nefrologia; 2005; 25 Suppl 2():15-8. PubMed ID: 16050396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Concentration of middle-sized molecules in the blood of children with chronic renal failure during treatment with short-term hemodialysis].
    Gudim VI; Sigalla P; Ivanova VS; Oldag K
    Vopr Med Khim; 1980; 26(6):742-6. PubMed ID: 7456404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of serum reverse triiodothyronine and thyroxine kinetics in chronic renal failure: role of nutritional status, chronic illness, uremia, and hemodialysis.
    Kaptein EM; Feinstein EI; Nicoloff JT; Massry SG
    Kidney Int Suppl; 1983 Dec; 16():S180-6. PubMed ID: 6588250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dialysis therapy: 'think differently'.
    Perrone B
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
    Popławski A; Myśliwiec M; Soszka J
    Pol Tyg Lek; 1990 Oct 1-8; 45(40-41):810-3. PubMed ID: 2096374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of uremic middle molecules in regular hemodialysis patients.
    Asaba H; Alvestrand A; Fürst P; Bergström J
    Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High molecular substances in relation to disorders of erythropoiesis in patients in the terminal stage of chronic renal failure].
    Gudim WI; Sukiasowa TG; Iwanowa WS; Gorbunowa NA; Kosinez GI
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(6):834-44. PubMed ID: 2453413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.